About Macumira

A New Era in Dry AMD Therapy for Australia & New Zealand

MacuMira is transforming how dry age-related macular degeneration (dry AMD) is managed, offering a noninvasive treatment designed to improve visual function with comfort, precision, and safety.

At MacuMira, we bring a sense of purpose to everything we do. Our goal is to equip eye care professionals with a meaningful tool that helps preserve and enhance vision for people affected by this life-altering disease.

Now available across Australia and New Zealand, MacuMira is redefining what is possible in dry AMD care.

Learn More

Our Mission

To improve visual function and quality of life for the more than 400 million people around the world who live with dry AMD, and to help make MacuMira a recognised standard of care in Australia, New Zealand, and beyond.

A Brief History of Microcurrent Therapy

Microcurrent therapy has been used in medical treatment since the mid-20th century and has emerged as a groundbreaking approach in medical treatment. Its ability to mimic the body’s natural electrical signals has made it a valuable tool in tissue repair and healing.

These gentle currents play a crucial role in key cellular healing processes. Early research by Assimacopoulos (1968) and Wolcott et al. (1969) demonstrated that microcurrent could support faster tissue repair and regeneration by improving intercellular communication and increasing ATP production—ATP being the fuel cells use for energy.

MacuMira builds on this foundation with a patented waveform and refined delivery system. By directing this therapy through closed eyelids, MacuMira helps stimulate healthy retinal activity and may lead to clinically measurable improvements in visual function for people with dry AMD.

MacuMira uses a unique, patented waveform controlled by sophisticated coding to deliver safe, effective retinal rejuvenation that can improve vision in patients living with dry AMD.